Roivant Sciences Ltd.
Roivant Sciences (ROIV) reported that director Daniel Allen Gold had 5,133 shares withheld on September 10, 2026, to cover tax obligations related to a vesting equity grant. The shares were valued at $40.94 each, totaling $210K. Gold still holds 8,960,761 shares directly.
Roivant Sciences (ROIV) director Melissa B. Epperly had 2,179 shares withheld for tax obligations on September 10, 2026, leaving her with 14,838 shares. The shares were withheld at $40.94 per share to cover taxes on vested equity awards.
Dell (DELL) hit a record $538.47 due to AI demand and S&P 100 inclusion. Roivant (ROIV) surged to $42.50 after positive drug data. Shell (SHEL) reached $95.80 on Gulf of America stake and Morgan Stanley upgrade. Each stock gained 1-18% Tuesday.
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning ROIV (Roivant Sciences Ltd.). Coverage has skewed bullish: 2 bullish, 3 neutral, and 0 bearish.
Recent ROIV coverage spans technology, financial news and market movers.
In the last 30 days, ROIV insiders filed 10 SEC Form 4 transactions — no purchases and 10 sales ($20.7M). The most active reporter was Fitzgerald Meghan with 3 filings. 70% of those filings were made under pre-arranged Rule 10b5-1 plans.
Small insider tax‑withholding transaction of $210K.
Small insider tax‑withholding transaction; unlikely to move the stock materially.
Positive Phase 2 data could unlock multi‑billion‑dollar sales potential.
Positive Phase 2 data suggests significant commercial potential and may lift the stock further pending Phase 3.
The insider sale adds modest supply and may signal confidence level, but the amount is small relative to market cap.
AlphAI scores every news story that mentions ROIV with an AI model for sentiment and relevance, and aggregates insider trades from Roivant Sciences Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Roivant Sciences (ROIV) reported that director Daniel Allen Gold had 5,133 shares withheld on September 10, 2026, to cover tax obligations related to a vesting equity grant. The shares were valued at $40.94 each, totaling $210K. Gold still holds 8,960,761 shares directly.
1 min readRoivant Sciences (ROIV) director Melissa B. Epperly had 2,179 shares withheld for tax obligations on September 10, 2026, leaving her with 14,838 shares. The shares were withheld at $40.94 per share to cover taxes on vested equity awards.
1 min readDell (DELL) hit a record $538.47 due to AI demand and S&P 100 inclusion. Roivant (ROIV) surged to $42.50 after positive drug data. Shell (SHEL) reached $95.80 on Gulf of America stake and Morgan Stanley upgrade. Each stock gained 1-18% Tuesday.
2 min readRoivant Sciences (ROIV) shares rose 18% after reporting positive Phase 2 results for Mosliciguat, a pulmonary hypertension treatment. The drug showed a 56.3% reduction in pulmonary vascular resistance and a 35.2-meter improvement in six-minute walk distance. Analysts suggest potential $10B annual sales. Success in Phase 3 trials is critical for commercialization and long-term growth.
2 min readRoivant Sciences (ROIV) director Meghan Fitzgerald exercised 20,000 stock options at $8.80 per share and sold 20,000 shares at an average price of $39.95 per share under a Rule 10b5-1 trading plan on September 8, 2026. She still holds 18,578 options, exercisable until 2033.
1 min readFitzgerald Meghan sold 20,000 shares of Roivant Sciences Ltd. (ROIV) at $39.90 ($0.80M total) on 2026-09-08 under a Rule 10b5-1 trading plan.
1 min readDell (DELL), Roivant (ROIV), and Shell (SHEL) hit 52-week highs. Dell rose 1% on AI demand and S&P 100 inclusion, with Q2 AI server revenue near $74B. Roivant gained 18% on positive clinical trial results for mosliciguat. Shell climbed 2% on Gulf of Mexico expansion and a Morgan Stanley upgrade.
2 min readRoivant Sciences (ROIV) hit an all-time high after reporting positive results from its PH-ILD treatment trial. The drug, mosliciguat, met primary and secondary endpoints, reducing PVR by 56.3% and improving walking distance. Jefferies raised its price target to $52. Hedge fund holdings surged 41% in Q2.
2 min readBluejay Diagnostics (BJDX) partnered with Lovell Government Services for federal healthcare market access, trading at $1.05, up 27.4%. Pharvaris (PHVS) reported 83% attack rate reduction in HAE study, trading at $37.82, up 7.02%. Roivant (ROIV) showed positive Phase 2 results for mosliciguat, trading at $41.35, up 18.35%. Atara Biotherapeutics (ATRA) updated BLA resubmission plans, trading at $10.71, up 9.73%. PDS Biotech (PDSB) raised $22.55M in PIPE financing, trading at $0.29, up 33.21%.
3 min readRoivant Sciences (ROIV) and Pharvaris (PHVS) reached record highs after positive clinical trial results. Roivant's drug, mosliciguat, showed a 56.3% improvement in lung blood flow resistance over 16 weeks. Both companies' stocks surged on the news.
1 min read
